NCT07038603Completed
Feasibility of a Behavioural Activation Protocol to Support People With Parkinson's Enhanced by VR
Assessing the Feasibility of Behavioural Activation (BA) to Support People With Parkinson's Disease Enhanced by a Virtual Reality Exercise Programme
Source: ClinicalTrials.gov · Last updated 26 Jun 2025
Brief summary (registry, in English)
The proposed research project will involve developing and testing the feasibility of a 6 week Behavioural Activation (BA) programme for people with Parkinson's Disease, which will be enhanced by Virtual Reality exercise programme. The aim of the programme will be to support the mental well-being and physical rehabilitation of people with Parkinson's Disease who are known to Marie Curie Outpatient Department (Belfast). The main question\[s\] it aims to answer are: Is a Behavioural Activation (BA) enhanced by a Virtual Reality exercise programme feasible and can it support the mental well-being and physical rehabilitation of People with Parkinson's Disease ? Can the potential impacts of the intervention help to reduce anxiety and depression, as well as improve balance, social interaction and adherence to the programme? Participants will: * Attend a group for 6 weeks with the addition of an introductory session, for 1.5 hours per session. * During sessions they will be asked to take part in a Behavioural Activation talking therapy. The aim of the intervention is to engage patients through activation strategies and help support adherence to exercise programmes. Participants will complete 'homework' tasks between sessions. * In addition to this, the BA intervention will be enhanced by Virtual Reality exercises and participants will complete exercises within the immersive space using a VR headset. * Data collection will capture any changes in depression, anxiety, balance,social interaction and adherence to the programme. * The intervention will be carried out in three phases.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 13 (actual)
- First submitted
- 19 Feb 2024
- Start date
- 5 Apr 2023
- Primary completion date
- 20 Dec 2023
- Lead sponsor
- Queen's University, Belfast
- Diseases
- Parkinson disease
- NCT number
- NCT07038603
What you commit to
- Study type: Interventional
- Participants enrolled: 13
- From 5 Apr 2023 to the primary completion date, 20 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Not receiving another form of psychotherapy
Other illness
- No other Neurological Condition
- Vision/ auditory impairment.
- Carers and healthcare staff:
Other
- Those who are unwilling/unable to provide written consent to participate
- Actively suicidal
- Those who are unwilling/unable to provide written consent to participate
Who the study is looking for
- Patients with a diagnosis of Idiopathic Parkinson's Disease which has been diagnosed by a neurologist.
- Patients with an early to moderate disease stage Hoehn and Yahr scale 1-3
- Patients with a BERG Balance Scale \> 45
- Currently not attending any other rehab programme/participation in another clinical trial
- Able to exercise independently \& mobilise
- No hospitalisation or medication change within the past month
- No other serious medical or surgical condition
- Carers:
- Have direct contact with a participant on the BAPP-VR programme in the role of a carer.
- Healthcare staff:
- Have helped in some capacity to facilitate the intervention or referred patients to BAPP-VR
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Marie Curie Coordinator of this site? Confirm its status | Belfast | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.